## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	ırden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)			2 1-	NT		C: -1	T 1:-	Cl1	5 E	5 Palationship of Paparting Parson(s) to Issuar					
1. Name and Address of Reporting Person VANCE DOLLY  (Last) (First) (Middle)  RIGEL PHARMACEUTICALS, INC., 1180  VETERANS BLVD.  (Street)  SOUTH SAN FRANCISCO, CA 94080			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]      3. Date of Earliest Transaction (Month/Day/Year)     02/06/2020  4. If Amendment, Date Original Filed(Month/Day/Year)						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Ill'(Nomer  X Officer (give title below) Other (specify below)  EVP Corp. Affairs, G.C., Sect.  6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
								X							
								_X_					)		
(City) (State) (Zip)			(Zip)			T	able I	- Non-Deri	ivative Securiti	es Acquired	l iired, Disposed of, or Beneficially Owned				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		Execution Date, if Cod			(Instr. 3, 4 and (A) o		Owned Follow Transaction(s) (Instr. 3 and 4)		ring Reported (		Ownership of B	Beneficial Ownership			
Reminder:	Report on a	separate line for each	h class of securities b	eneficial	lly ow	vned direc	etly or	Person	s who respon form are not r						474 (9-02)
Reminder:	Report on a	separate line for eacl		- Deriva	ntive S	Securities	s Acqu	Person in this a curre	form are not rently valid OMI  osed of, or Bene	equired to B control n	respond ι umber.				474 (9-02)
1. Title of Derivative Security (Instr. 3)	2.	3. Transaction	Table II  3A. Deemed Execution Date, if	- Deriva (e.g., p) 4. Transact Code	stive Suts, careful Stition I	Securities alls, warn	s Acquerants, or of le (A)	Person in this a curre uired, Dispo options, co	form are not rently valid OMI  osed of, or Beneral osecure of the secure	equired to B control n	respond umber. ned Amounting	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownersh Form of Derivati Security Direct (I or Indire	ip of Indire Benefici (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II  3A. Deemed Execution Date, if any	- Deriva (e.g., p) 4. Transact Code	stive Suts, careful Stition I	Securities alls, warn to be considered alls, warn to be considered and the considered are because the	s Acquerants, or of le (A)	Person in this is a curre uired, Dispositions, co	form are not r ntly valid OMI osed of, or Bene nvertible secur ercisable and Date y/Year)	equired to 3 control n eficially Own ities)  7. Title and of Underlying Securities	respond umber. ned Amounting	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownersh Form of Derivati Security Direct (I or Indire	ip of Indire Benefici (Instr. 4

### **Reporting Owners**

			Relationships	
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
VANCE DOLLY RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			EVP Corp. Affairs, G.C., Sect.	

### **Signatures**

/s/Dolly Vance	02/07/2020
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the issuer through each such period.

Potential persons who are to respond to the collection of information contained in this form are no	ot required to respond unless the form displays a currently valid OMB number.